Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Seaforth ...
I was thinking of a Tpl merge situation, where values of each company have been determined and agreed on. If we were to give them 20 mil shares, wouldn't some assessed value have been determined between the 2 companies? If that value was determined to be $10 mil.,(Just for example) wouldn't buying shares under that .50 range save the treasury/PTSC money? Shares going into the hands of the TPL principles would come at a cost, plus possible dilution if unregistered shares were needed, right? An issuing of new shares ..in that situation, seems even more messy. joe
Share
New Message
Please login to post a reply